Gilead Sciences ( (GILD) ) has released its Q2 earnings. Here is a breakdown of the information Gilead Sciences presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences, Inc. is a biopharmaceutical company focused on advancing innovative medicines to prevent and treat life-threatening diseases such as HIV, viral hepatitis, COVID-19, cancer, and inflammation, with operations in over 35 countries worldwide. In the second quarter of 2025, Gilead Sciences reported a 2% increase in total revenue, reaching $7.1 billion, driven by higher sales in HIV, Livdelzi, and Trodelvy products, despite a decline in Veklury sales due to lower COVID-19 hospitalizations. The company also achieved a significant milestone with the FDA approval of Yeztugo, the first twice-yearly HIV prevention option. Key financial metrics for the quarter included a diluted EPS of $1.56, up from $1.29 in the same period last year, and a non-GAAP diluted EPS of $2.01, remaining flat year-over-year. Gilead’s cash reserves stood at $7.1 billion as of June 30, 2025, down from $10.0 billion at the end of 2024, with operating cash flow generation of $827 million. Looking ahead, Gilead has raised its revenue and earnings guidance for the year, reflecting confidence in continued innovation and growth across its core therapeutic areas.